MYOV Myovant Sciences Ltd.

8.82
+0.23  (+3%)
Previous Close 8.59
Open 8.59
Price To Book 176.4
Market Cap 790,471,561
Shares 89,622,626
Volume 227,039
Short Ratio 4.25
Av. Daily Volume 363,111

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data 1Q 2020.
Relugolix - SPIRIT 1
Endometriosis-associated pain
Phase 3 data 1Q 2020.
Relugolix - SPIRIT 2
Endometriosis-associated pain
Phase 3 data due 4Q 2019.
Relugolix - HERO
Advanced prostate cancer
Phase 3 LIBERTY 1 top-line data met primary endpoint - May 14, 2019. LIBERTY 2 data due 3Q 2019.
Relugolix - LIBERTY 1 and LIBERTY 2
Menstrual bleeding associated with uterine fibroids

Latest News

  1. Myovant Sciences and Evidation Health Announce Partnership and Launch Digital Insights Study on Menstruation
  2. 3 Hot Insider Trading Stocks To Boost Your Portfolio
  3. Myovant Sciences to Present at Upcoming June Investor Conferences
  4. Here's Why Myovant Sciences Jumped Today
  5. The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering
  6. Myovant Sciences Announces Pricing of $125 Million Public Offering of Common Shares
  7. Myovant Sciences Announces $100 Million Public Offering of Common Shares
  8. Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
  9. Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea
  10. Biotech Stock Roundup: FDA Nod for REGN's Eylea in DR, Tie-Ups & Other Updates
  11. Myovant Shares Slide Despite Positive Late-Stage Data For Menstrual Bleeding Drug
  12. Myovant stock up 1.6% after Phase 3 trial meets endpoints
  13. Myovant Sciences' uterine fibroids combo therapy meets main goal in study
  14. Introducing Myovant Sciences (NYSE:MYOV), The Stock That Dropped 23% In The Last Year
  15. Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
  16. Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
  17. Here’s What Hedge Funds Think About Myovant Sciences Ltd. (MYOV)
  18. Myovant Sciences to Present at Upcoming Investor Conferences
  19. Myovant- "Value Creation" in Cancer Treatment
  20. 4 Disruptive Healthcare Stocks You've Never Heard Of